Peptide
Reference library
Educational peptide reference — research use only.
Research & educational use only
For laboratory and educational research only. Not for human or veterinary consumption. This is not medical advice. Always follow applicable laws and consult qualified professionals.
The calculator performs unit math for research reference. It must not be used to plan or guide dosing in humans or animals. Verify all figures independently in your lab protocol.
ARA290 (Cibinetide)
An EPO-derived peptide studied in neuropathic pain and tissue-protection research.
- Half-life (approx.)
- ~2–3 min (approx., IV); longer subQ
- Diluent
- Bacteriostatic water (0.9% benzyl alcohol)
- Common vials
- 2, 5 mg
Half-life figures are literature approximations for educational reference — not pharmacokinetic advice.
Overview
ARA290 (cibinetide) is an 11-amino-acid EPO-derived peptide that activates the innate repair receptor (IRR) in neuropathic-pain models. Clinical-adjacent research explores diabetic neuropathy and tissue protection without erythropoietic effects. EPO-derived IRR agonist (cibinetide) explored for neuropathic pain without hematopoietic effects.
Structure & identity
11-mer peptide QRIRRGDIGAG (EPO-derived)
- Sequence / structure
- 11-mer peptide QRIRRGDIGAG (EPO-derived)
Status: Investigational (cibinetide) for neuropathic pain.
Mechanism
Investigational (cibinetide) for neuropathic pain.
Activates innate repair receptor (IRR) heteromer without erythropoietin receptor signaling. IRR heteromer activation triggers tissue-protective signaling distinct from EPOR homodimers.
Studies & clinical programs
Diabetic neuropathy models
Published research models
- Peer-reviewed literature documents endpoints under Diabetic neuropathy models experimental designs.
Corneal nerve regeneration
Published research models
- Peer-reviewed literature documents endpoints under Corneal nerve regeneration experimental designs.
Research models in literature
- Diabetic neuropathy models
- Corneal nerve regeneration
Literature highlights
- Innate repair receptor (IRR) activation studied in diabetic neuropathy models.
- Corneal nerve regeneration and pain-behavior endpoints in rodent neuropathy research.
- Cibinetide development explored neuropathic pain without erythropoietic signaling.
Key targets & pathways
Research areas
Routes in research literature
Also known as
Stability & storage phases
| Phase | Condition | Guidance |
|---|---|---|
| Lyophilized | Sealed vial, refrigerated (2–8 °C) | Intact lyophilized cake or powder is typically stable for months to years per published stability data; protect from moisture, light, and repeated freeze-thaw of the dry vial. |
| Reconstituted | Bacteriostatic water (0.9% benzyl alcohol), refrigerated | Most aqueous peptide solutions remain usable for approximately 2–4 weeks refrigerated; verify published stability data and label with reconstitution date. |
| Working aliquots | Pre-drawn syringes or microtubes, frozen (−20 °C) | Aliquot promptly after mixing to limit freeze-thaw cycles on the main vial; thaw once and use to reduce protease-mediated degradation. |
Stability windows are formulation-dependent — verify published data and your lab SOP.
Reconstitution reference table
| Vial (mg) | Diluent (mL) | mcg/mL | Units @ 100 mcg | Units @ 250 mcg | Units @ 500 mcg |
|---|---|---|---|---|---|
| 2 | 2 | 1000.0 | 10 | 25 | 50 |
| 5 | 2 | 2500.0 | 4 | 10 | 20 |
U-100 insulin syringe scale (100 units = 1 mL). Illustrative only — not dosing guidance.
Reconstitution steps
- Allow vial to reach room temperature (15–30 min)
- Swab rubber stopper with alcohol prep pad
- Draw calculated bacteriostatic water into syringe
- Inject diluent slowly down vial wall — do not spray directly onto cake
- Gently swirl until fully dissolved — do not shake vigorously
- Label with date, concentration, and diluent volume
- Refrigerate and use within your lab stability window
Typically reconstituted with 1–2 mL bacteriostatic water.
Laboratory record checklist
- Compound identity recorded in lab notebook (name, lot, preparation date)
- Analytical identity cross-checked against published sequence or structure
- Potency or concentration documented from analytical certificate when available
- Purity or HPLC data filed when provided with research material
- Appearance noted: intact lyophilized cake or uniform powder
- Sterility / endotoxin report archived when available
- Storage temperature applied immediately per published stability guidance